227318-71-0

Basic information

• Product Name: EpetiriMod
• Synonyms: EpetiriMod;S 30563;1-(2-Methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine;851A;1-(2-methylpropyl)imidazo[4,5-c][1,5]naphthyridin-4-amine
• CAS NO: 227318-71-0
• Molecular Formula: C13H15N5
• Molecular Weight: 241.2917
• Mol File: 227318-71-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 469.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.36±0.1 g/cm3(Predicted)
• PKA: 4.17±0.50(Predicted)
• CAS DataBase Reference: EpetiriMod(CAS DataBase Reference)
• NIST Chemistry Reference: EpetiriMod(227318-71-0)
• EPA Substance Registry System: EpetiriMod(227318-71-0)

Safety Data

• Hazardous Substances Data: 227318-71-0(Hazardous Substances Data)

Upstream product

• 885483-02-3 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate 
• 227318-70-9 1-(2-methylpropyl)-5-oxido-1H-imidazo[4,5-c][1,5]naphthyridine 
• 227318-68-5 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridine 

Relevant articles and documents

POLYMORPHS OF 1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE ETHANESULFONATE

The invention provides various crystalline forms of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, pharmaceutical compositions, methods of making, and methods of use.

Pharmaceutical formulation comprising an immune response modifier

Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.